Back

Reduction in shock burden with catheter ablation versus escalated antiarrhythmic drug therapy: Insights from the VANISH trial

3 April 2022 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: News from ventricular ablation Ablation of Ventricular Arrhythmias EHRA Premium Access EHRA 2022

About the speaker

Photo
Associate Professor Michelle Samuel

Allegheny Health Network, Pittsburgh (United States of America)

5 More presentations in this session

Presentation thumbnail
Multimodality planning of stereotactic radio-ablation for ventricular tachycardia. Results from the international MUSIC consortium
Professor H. Cochet (Bordeaux, FR)
Abstract Slides Video
Presentation thumbnail
Area weighted unipolar voltage to predict heart failure death in patients with ischemic cardiomyopathy and ventricular tachycardia
Mr R. Rademaker (Leiden, NL)
Abstract Slides Video
Presentation thumbnail
Electroanatomic visualization of coronary arteries: a case series to elicit safety, feasibility and diagnostic value in complex ablation procedures
Doctor B. Fries (Landau in der Pfalz, DE)
Abstract Slides Video
Presentation thumbnail
Standardizing the cardiac radioablation targeting workflow: enabling semi-automated angulation and segmentation of the heart according to the American Heart Association segmented model
Mr M. van der Ree (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
The outcome spectrum for Dilated Cardiomyopathy and Ventricular Tachycardia: results from the prospective, multicenter, DCM-VT ablation study
Doctor A. Wijnmaalen (Leiden, NL)
Abstract Slides Video

Access the full session

Session thumbnail
News from ventricular ablation

The Event

Event poster

EHRA 2022

3 April - 5 April 2022
You may be interested in
thumbnail
Congress Presentation
Case 2 - implantable cardioverter defibrillator, catheter ablation, or both for secondary prevention?
thumbnail
Congress Presentation
Case 1 - first choice treatment: antiarrhythmic drugs or catheter ablation?
thumbnail
Congress Presentation
Ablation is alternative to ICD therapy in post-myocardial infarction patients with haemodynamically well-tolerated sustained monomorphic VT and LVEF>40%: con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources